HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Senior Research Scientist, Dr. Chuo Fang M.D., Ph.D., delivered a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting that took place in San D ...

Production debut of the De Tomaso P72 underscores brand strength and commercial readiness as ESGL business combination advancesSINGAPORE, May 16, 2025 (GLOBE NEWSWIRE) -- ESGL Holdings Limited (NASDAQ: ESGL), a leader in sustainable circular solutions, announces a major milestone in its strategic merger with De Tomaso Automobili: the official unveiling of the production specification P72. This event reinforces the strong operational and brand foundation of the combined company, as the proposed business comb ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Warner Music Group Corp. (“Warner Music Group” or “WMG”) today announced that its Board of Directors declared a regular quarterly cash dividend of $0.18 per share on WMG’s Class A Common Stock and Class B Common Stock. The dividend is payable on June 3, 2025, to stockholders of record as of the close of business on May 27, 2025. About Warner Music Group With a legacy extending back over 200 years, Warner Music Group today is home to an unparalleled family of creati ...

Not for distribution to U.S. news wire services or dissemination in the United States MARKHAM, Ontario, May 16, 2025 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, announced today that the previously announced secondary bought deal offering (the “Offering”) of 5,200,000 common shares of the Company (the “Common Shares”) by PV Holdings S.à r.l., Roark Capital Partners II AIV AG, L.P., RCPS Equi ...

Group 1 - Oxford Lane Capital Corp. has been awarded "Best Public Closed-End CLO Fund" by Creditflux, recognizing its performance in the CLO sector [1][2] - The award was presented at the Creditflux Credit Symposium and Manager Awards held in London on May 15, 2025, based on data from December 31, 2023, to December 31, 2024 [2] - Jonathan Cohen, CEO of Oxford Lane, expressed gratitude towards the team and partners for their contributions to this achievement [3] Group 2 - Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company that primarily invests in debt and equity tranches of CLO vehicles [3]

Core Viewpoint - The company has allotted 2,539,174 Ordinary Shares under its Dividend Reinvestment Scheme at a price of 51.4p per share, increasing its total shares in issue to 315,317,284 [1][2]. Group 1 - The allotment of shares occurred on 16 May 2025 [1]. - The shares were issued at a price of 51.4p each [1]. - The company has applied for the admission of these shares to the Official List of the UK Listing Authority and for trading on the London Stock Exchange, expected around 20 May 2025 [2]. Group 2 - Following the allotment, the total number of Ordinary Shares in issue is now 315,317,284 [2]. - For further inquiries, contact Gary Fraser at Foresight Group [2].

Core Points - The CEO of Alstom, Henri Poupart-Lafarge, has decided not to seek a fourth term, with his current term ending at the General Meeting for the financial year ending March 31, 2027 [1] - The Board of Directors is initiating the process to identify a successor to ensure a smooth transition [1] - The Board expressed satisfaction with the annual results published on May 14, highlighting the effectiveness of Poupart-Lafarge's management [2] - Poupart-Lafarge will continue as CEO until a successor is appointed [2] Company Overview - Alstom is committed to a low carbon future by developing sustainable transportation solutions, including high-speed trains, metros, and digital mobility services [3] - The company operates in 63 countries and employs over 86,000 people from 184 nationalities [3] - For the fiscal year ending March 31, 2025, Alstom generated sales of €18.5 billion [3]

Core Points - An Extraordinary General Meeting (EGM) of Prosafe SE was held virtually on 16 May 2025 [1] - All proposals on the agenda were adopted as per the notice published on 25 April 2025 [1] - Minutes from the EGM are available for download from specified links [1] Company Information - The EGM was conducted via Lumi platform [1] - Contact information for CEO Terje Askvig and CFO Reese McNeel is provided for further inquiries [1] - The information is disclosed in accordance with the Norwegian Securities Trading Act [1]

Core Insights - Mainz Biomed N.V. plans to provide an interim readout of its eAArly DETECT 2 feasibility study by the end of summer 2025, with top-line results expected in Q4 2025 [1][2] - The study aims to validate a next-generation colorectal cancer screening test that combines proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test on approximately 2,000 average-risk patients [1][3] - The company is on track to initiate its U.S. pivotal trial, ReconAAsense, in 2026 based on the outcomes of the eAArly DETECT 2 study [2][3] Study Details - The eAArly DETECT 2 study is expected to complete enrollment in the second half of 2025, targeting the reporting of top-line results by Q4 2025 [2] - The study will evaluate the effectiveness of five novel mRNA biomarkers acquired from Sherbrooke University in 2022, which have shown the ability to identify advanced adenomas and early-stage colorectal cancer [3] Company Mission - The company aims to advance its mission of eliminating colorectal cancer and reducing global cancer mortality rates through precise detection of advanced precancerous lesions and early-stage colorectal cancer [3]

WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. “The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a reve ...